<DOC>
	<DOCNO>NCT00121888</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness tolerability controlled-release paroxetine ( Paxil-CR ) compare placebo ( inactive substance ) individual continue symptom post traumatic stress disorder ( PTSD ) despite receive prolonged exposure therapy .</brief_summary>
	<brief_title>Trial Paroxetine-CR Treatment Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy</brief_title>
	<detailed_description>Post Traumatic Stress Disorder ( PTSD ) common general population National Comorbidity Survey report lifetime prevalence 8 % United States ( Kessler , et al 1995 ) . PTSD associate marked symptomatic distress well significant impairment , dysfunction reduction overall quality life ( Kessler , 2000 ) . Both pharmacotherapeutic intervention , include serotonin selective reuptake inhibitor ( SSRIs ) , psychosocial intervention cognitive-behavior therapy ( CBT ) demonstrate efficacy PTSD ( Davidson , 2001 ; Foa , 2000 ) However , although intervention helpful , many patient remain symptomatic despite initial treatment . There little data available guide practice regard efficacy `` next step '' strategy patient remain symptomatic despite treatment . In study researcher examine relative efficacy addition SSRI , paroxetine-CR , compare placebo patient remain symptomatic despite brief intensive course CBT . This two phase , 14-16 week research study participant remain symptomatic end one phase ( 4-6 week ) enter next phase . In phase I , participant receive prolong exposure ( PE ) therapy . Participants continue significant distress posttraumatic stress disorder 8 session therapy enter Phase II . In Phase II subject receive 5 session PE therapy randomly assign ( chance , like flip coin ) receive paroxetine-cr ( Paxil-CR ) placebo ( contains active medication ) . Participants receive combine treatment next 10 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male female outpatient least 18 year age primary ( condition central patient 's current distress ) psychiatric diagnosis PTSD define DSMIV criterion . Patients must remain symptomatic ( CGIS &gt; 3 ) score least 6 Short PTSD Rating Interview ( SPRINT ) minimum 7 session PE ( deliver within 6 week ) eligible randomize treatment . Patients exclude study serious medical illness instability hospitalization may likely within next three month . Pregnant lactate woman childbearing potential use medically accept form contraception exclude . Concurrent use psychotropic medication ; psychotropic medication ( exclude benzodiazepine ) must stop least one week prior entry initial PE phase study . Patients may remain concomitant benzodiazepine ( &lt; 2 mg/d clonazepam equivalent ) , long benzodiazepine therapy initiate least 2 month prior randomization constant dose &gt; 4 week prior randomization ; dose hold constant study . Lifetime diagnosis schizophrenia psychosis , mental retardation , organic mental disorder , bipolar disorder ; obsessivecompulsive disorder , eat disorder , cut significant selfinjurious behavior alcohol/substance abuse disorder within last 6 month , study exclusion . Patients current primary diagnosis major depression , dysthymia , social anxiety disorder generalize anxiety disorder exclude presence disorder permissible long PTSD predominant disorder . Patients history hypersensitivity poor response paroxetine exclude . Concurrent dynamic supportive psychotherapy permit long ongoing least 2 month prior onset study entry . Patients current compensation legal action related effect trauma , ongoing relationship assailant . Patients positive toxicology screen baseline consistent evidence current substance abuse dependence determine clinical interview .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>post traumatic stress disorder</keyword>
	<keyword>Prolonged Exposure Therapy</keyword>
	<keyword>pharmacotherapy</keyword>
	<keyword>double-blind</keyword>
	<keyword>Anxiety Disorder</keyword>
</DOC>